Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Publishes Data on Cancer of Unknown Primary Origin Test

Premium

Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.

In a paper published in The Oncologist, company researchers reported that the test could use microRNA signatures to identify 42 tumor types with high accuracy, maintaining the performance across patient samples.

“In the study, the assay was first validated on 509 samples of known origin in a blinded manner and demonstrated 85 percent accuracy, with the vast majority of samples resulting in a single reported origin, which was accurate in 90 percent of the cases,” Rosetta said. Clinico-pathologic evaluation validated the performance of the assay in bona fide CUP cases.

The publication comes on the heels of Rosetta's announcement that miRview Mets 2 had received Medicare coverage (GSN 5/17/2012).

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.